Cagrilintide brand details are still unconfirmed: Novo Nordisk develops the amylin analog as CagriSema, and no trade name is approved in the US yet.
Cagrilintide does not currently have an approved brand name in the United States. It is an investigational amylin analog developed by Novo Nordisk, a Danish pharmaceutical company that also markets Ozempic and Wegovy. The name most people see in news coverage, CagriSema, refers to a combination product that pairs cagrilintide with semaglutide — not a brand of cagrilintide on its own.
Many people searching this topic are really asking what is cagrilintide, and the short answer is this: it is a synthetic, long-acting version of amylin, a hormone your pancreas releases alongside insulin to slow stomach emptying and reduce appetite.
Does Cagrilintide Have a Brand Name Yet?
No. Cagrilintide has a generic (nonproprietary) name, but no trade name has been approved for it anywhere.
The naming gets confusing because three different labels get mixed together online:
- Cagrilintide — the generic name of the single molecule.
- CagriSema — a development name for the fixed-dose combination of cagrilintide and semaglutide 2.4 mg.
- Brand name — a commercial name a manufacturer may use only after regulatory approval. That step has not happened.
Cagrilintide is not FDA-approved for any indication, including weight loss or type 2 diabetes. Any website advertising a cagrilintide brand for sale is selling something that has never cleared the FDA review process.
The Company Behind Cagrilintide: Novo Nordisk
Novo Nordisk is the company developing cagrilintide. The molecule came out of the company's research into amylin analogs, and every major human trial of cagrilintide has been run or sponsored by Novo Nordisk.
That matters for a practical reason. Because Novo Nordisk holds the rights, no other manufacturer can legally sell a branded or generic cagrilintide product until patents and market exclusivity expire or a licensing deal is reached.
The company's existing portfolio is a reasonable indicator of what a future launch could look like:
- Ozempic (semaglutide) for type 2 diabetes
- Wegovy (semaglutide) for chronic weight management
- Rybelsus (oral semaglutide)
- Saxenda and Victoza (liraglutide)
Novo Nordisk has said it intends to pursue regulatory filings for CagriSema, but a filing is not an approval, and a filing does not create a brand name by itself.
How Cagrilintide Compares With Tirzepatide and Retatrutide
The compounds most often mentioned alongside cagrilintide come from two different companies and work through different hormone pathways.
| Compound | Mechanism | Developer | Known brand names | Status |
|---|---|---|---|---|
| Cagrilintide | Amylin analog | Novo Nordisk | None (studied as CagriSema) | Investigational |
| Semaglutide | GLP-1 receptor agonist | Novo Nordisk | Ozempic, Wegovy, Rybelsus | FDA-approved |
| Tirzepatide | GIP and GLP-1 dual agonist | Eli Lilly | Mounjaro, Zepbound | FDA-approved |
| Retatrutide | GLP-1, GIP, and glucagon triple agonist | Eli Lilly | None | Investigational |
The clearest takeaway from a head-to-head reading of cagrilintide vs tirzepatide is that only one of those two has an approved product a doctor can prescribe today. Tirzepatide holds FDA approval; cagrilintide does not.
A three-way look at cagrilintide vs retatrutide vs tirzepatide mostly highlights mechanism. Tirzepatide targets two hormone receptors, retatrutide targets three, and cagrilintide works through the amylin pathway instead of the incretin pathway — which is why researchers tend to describe it as complementary rather than purely competitive.
What Trials Have Shown: Dosing and Side Effects
In clinical trials, cagrilintide has been given as a once-weekly subcutaneous injection with a slow dose-escalation phase. That pattern is what a future label would likely follow, though no official cagrilintide dosage exists because the drug is unapproved.
Reported cagrilintide side effects resemble those of other appetite-regulating injectables and are mostly gastrointestinal:
- Nausea
- Vomiting
- Diarrhea or constipation
- Injection-site reactions
- Early fullness and reduced appetite
In the REDEFINE 1 trial of CagriSema, Novo Nordisk reported mean weight loss of roughly 22.7% at 68 weeks in the flexible-dose group. Those results have not been reviewed by the FDA, and trial results do not guarantee approval or real-world performance.
Anyone considering an amylin-based therapy should talk with a licensed healthcare professional rather than self-treating. Long-term safety data for cagrilintide in humans is still limited.
Can You Buy Cagrilintide Right Now?
No. Cagrilintide is not available by prescription in the United States, and it is not stocked in pharmacies. The only legitimate way to receive it is by enrolling in a clinical trial.
Powders labeled cagrilintide from online research chemical sellers are unregulated. They are not produced under FDA oversight, their purity is unverified, and their identity is often assumed rather than tested. Injecting an unverified peptide carries real risk of contamination and dosing errors.
Some forum posts describe stacking cagrilintide alongside other weight-loss drugs, but no published human trial has tested those combinations. Mixing unapproved and approved medications without medical supervision is not a supported practice.
What to Watch For Next
If cagrilintide eventually reaches the market, three steps happen in sequence:
- Novo Nordisk submits a new drug application or an equivalent filing to regulators.
- Regulators review the data and issue an approval decision.
- A trade name is assigned and published — that becomes the cagrilintide brand.
Until that sequence is complete, the most accurate answer is that no cagrilintide brand exists yet. The molecule is real, the company is known, and the commercial name is still pending.
Frequently Asked Questions
Does cagrilintide have a brand name?
No. Cagrilintide is still an investigational drug, so no trade name has been approved for it in the United States. CagriSema is a development name for the combination of cagrilintide and semaglutide, not an approved brand of cagrilintide by itself.
Which company makes cagrilintide?
Novo Nordisk is the company developing cagrilintide. The Danish manufacturer also markets semaglutide products such as Ozempic and Wegovy and is running the Phase 3 REDEFINE trials of CagriSema.
Can I get cagrilintide prescribed in the US?
No. Cagrilintide is not FDA-approved, so no pharmacy or telehealth provider can legally prescribe it. The only way to receive cagrilintide today is by enrolling in a clinical trial, and unregulated research chemical sellers are not a safe substitute.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.